Axura

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
26-02-2024
Opinber matsskýrsla Opinber matsskýrsla (PAR)
05-01-2012

Virkt innihaldsefni:

memantine hydrochloride

Fáanlegur frá:

Merz Pharmaceuticals GmbH

ATC númer:

N06DX01

INN (Alþjóðlegt nafn):

memantine

Meðferðarhópur:

Other anti-dementia drugs

Lækningarsvæði:

Alzheimer Disease

Ábendingar:

Treatment of patients with moderate to severe Alzheimer's disease.

Vörulýsing:

Revision: 27

Leyfisstaða:

Authorised

Leyfisdagur:

2002-05-17

Upplýsingar fylgiseðill

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
AXURA 10 MG FILM-COATED TABLETS
Memantine hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Axura is and what it is used for
2.
What you need to know before you take Axura
3.
How to take Axura
4.
Possible side effects
5.
How to store Axura
6.
Content of the pack and other information
1.
WHAT AXURA IS AND WHAT IT IS USED FOR
HOW DOES AXURA WORK
Axura contains the active substance memantine hydrochloride.
Axura belongs to a group of medicines known as anti-dementia
medicines.
Memory loss in Alzheimer’s disease is due to a disturbance of
message signals in the brain. The brain
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are
involved in transmitting nerve
signals important in learning and memory. Axura belongs to a group of
medicines called NMDA-
receptor antagonists. Axura acts on these NMDA-receptors improving the
transmission of nerve
signals and the memory.
WHAT IS AXURA USED FOR
Axura is used for the treatment of patients with moderate to severe
Alzheimer’s disease.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AXURA
DO NOT TAKE AXURA
-
if you are allergic (hypersensitive) to memantine hydrochloride or any
of the other ingredients
of Axura tablets (listed in section 6).
WARNING AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Axura
-
if you have a history of epileptic seizures
-
if you have recently experienced a myocardial infarction (heart
attack), or if you are suffering
from conges
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Axura 10 mg film-coated tablets
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Axura 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Axura 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Each filmcoated tablet contains 5 mg of memantine hydrochloride
equivalent to 4.15 mg memantine.
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Each film-coated tablet contains 15 mg of memantine hydrochloride
equivalent to 12.46 mg memantine.
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
Axura 20 mg film-coated tablets
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Axura 10 mg film-coated tablets
Pale yellow to yellow, oval shaped film-coated tablet with breaking
line and engravings "1-0" on one
side and "M M" on the other side.
The tablet can be divided into equal doses.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
The 5 mg film-coated tablets are white to off-white, oval-oblong
film-coated tablets with imprint ‘5’ on
one side and imprint ‘MEM’ on the other side.
The 10 mg film-coated tablets are pale yellow to yellow, oval shaped
film-coated tablet with breaking
line and engravings "1-0" on one side and "M M" on the other side. The
tablet can be divided into
equal doses.
The 15 mg film-coated tablets are orange to grey-orange, oval-oblong
film-coated tablets with imprint
‘15’ on one side and imprint ‘MEM’ on the other side.
The 20 mg film-coated tablets are pale red to grey-red, oval-oblong
film-coated tablets with imprint ‘20’
on one side and imprint ‘MEM’ on the other side.
Axura 20 mg film-coated tablets
Pale red to grey-red,
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 26-02-2024
Vara einkenni Vara einkenni búlgarska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla búlgarska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 26-02-2024
Vara einkenni Vara einkenni spænska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla spænska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 26-02-2024
Vara einkenni Vara einkenni tékkneska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla tékkneska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 26-02-2024
Vara einkenni Vara einkenni danska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla danska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 26-02-2024
Vara einkenni Vara einkenni þýska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla þýska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 26-02-2024
Vara einkenni Vara einkenni eistneska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla eistneska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 26-02-2024
Vara einkenni Vara einkenni gríska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla gríska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 26-02-2024
Vara einkenni Vara einkenni franska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla franska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 26-02-2024
Vara einkenni Vara einkenni ítalska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla ítalska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 26-02-2024
Vara einkenni Vara einkenni lettneska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla lettneska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 26-02-2024
Vara einkenni Vara einkenni litháíska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla litháíska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 26-02-2024
Vara einkenni Vara einkenni ungverska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla ungverska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 26-02-2024
Vara einkenni Vara einkenni maltneska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla maltneska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 26-02-2024
Vara einkenni Vara einkenni hollenska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla hollenska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 26-02-2024
Vara einkenni Vara einkenni pólska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla pólska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 26-02-2024
Vara einkenni Vara einkenni portúgalska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla portúgalska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 26-02-2024
Vara einkenni Vara einkenni rúmenska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla rúmenska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 26-02-2024
Vara einkenni Vara einkenni slóvakíska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 26-02-2024
Vara einkenni Vara einkenni slóvenska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvenska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 26-02-2024
Vara einkenni Vara einkenni finnska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla finnska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 26-02-2024
Vara einkenni Vara einkenni sænska 26-02-2024
Opinber matsskýrsla Opinber matsskýrsla sænska 05-01-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 26-02-2024
Vara einkenni Vara einkenni norska 26-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 26-02-2024
Vara einkenni Vara einkenni íslenska 26-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 26-02-2024
Vara einkenni Vara einkenni króatíska 26-02-2024

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu